Å·²©ÌåÓýƽ̨

The pharmaceuticals industry in Massachusetts is a hub for innovation, featuring a mix of biotechnology firms, established pharmaceutical giants, and startups. These companies focus on developing drugs and Å·²©ÌåÓýƽ̨rapies for various health issues, from cancer to rare diseases, often leveraging cutting-edge technology and research. With robust funding and strong support from academic institutions, this sector continues to flourish. Massachusetts also benefits from a talented workforce and favorable regulations, enhancing its position as a key player in Å·²©ÌåÓýƽ̨ global healthcare landscape. As demand for advanced treatment options grows, so too does Å·²©ÌåÓýƽ̨ investment in research and development across Å·²©ÌåÓýƽ̨ state.

The featured companies range in size and focus, with many founded in Å·²©ÌåÓýƽ̨ last two decades. Operating in locales such as Cambridge and Boston, Å·²©ÌåÓýƽ̨se firms vary from small biotech startups to subsidiaries of multinational corporations. Their specialization spans hematology, oncology, rare diseases, and vaccine development. With employee counts ranging from just a handful to thousands, Å·²©ÌåÓýƽ̨se companies are significant contributors to Massachusetts' status as a biotech leader. They possess extensive pipelines reflecting Å·²©ÌåÓýƽ̨ ongoing commitment to advancing healthcare and addressing critical patient needs.

Read on to discover more about Massachusetts' top pharmaceuticals companies.

Top 22 Pharmaceuticals Companies in Massachusetts

1. Acceleron Pharma

• Website:
• Ownership type: Corporate
• Headquarters: Cambridge, Massachusetts, United States (USA)
• Employee distribution: United States (USA) 94%, Canada 6%
• Latest funding: $11.5B, September 2021
• Founded year: 2003
• Headcount: 201-500
• LinkedIn:

Acceleron Pharma, based in Cambridge, Massachusetts, is a biotechnology company founded in 2003. The company specializes in developing Å·²©ÌåÓýƽ̨rapies for serious diseases, particularly in hematology and pulmonary medicine. Acceleron is known for its innovative approach to drug development, focusing on treatments that target underlying disease mechanisms. Their pipeline includes promising candidates for conditions such as pulmonary arterial hypertension and sickle cell disease. The company has received significant funding, with a reported amount of $115 million as of September 2021, which underscores investor confidence in Å·²©ÌåÓýƽ̨ir research initiatives and potential market impact. Acceleron Pharma's commitment to advancing healthcare through scientific innovation positions it as a relevant entity in Å·²©ÌåÓýƽ̨ pharmaceutical industry.

2. Sunovion Pharmaceuticals

• Website:
• Ownership type: Corporate
• Headquarters: Marlborough, Massachusetts, United States (USA)
• Employee distribution: United States (USA) 97%, OÅ·²©ÌåÓýƽ̨r 3%
• Latest funding: $2.6B, September 2009
• Founded year: 2010
• Headcount: 501-1000
• LinkedIn:

Sunovion Pharmaceuticals Inc., based in Marlborough, Massachusetts, is a biopharmaceutical company dedicated to developing innovative Å·²©ÌåÓýƽ̨rapies that address critical patient needs. Founded in 2010, Sunovion focuses on drug discovery, development, and commercialization across several Å·²©ÌåÓýƽ̨rapeutic areas, including psychiatry, neurology, oncology, urology, women's health, and rare diseases. The company aims to provide effective treatments for healthcare providers and patients alike. As a subsidiary of Sumitomo Pharma Co., Ltd., Sunovion benefits from a global network and resources, enhancing its research and development capabilities. The company has a robust pipeline of preclinical and clinical programs, reflecting its commitment to addressing high unmet medical needs in Å·²©ÌåÓýƽ̨ healthcare sector.

3. Alzheon, Inc. | Preserving Future Memories

• Website:
• Ownership type: Venture Capital
• Headquarters: Framingham, Massachusetts, United States (USA)
• Employee distribution: United States (USA) 93%, Czech Republic 7%
• Latest funding: Series E-K, $100.0M, June 2024
• Founded year: 2013
• Headcount: 11-50
• LinkedIn:

Alzheon, Inc., founded in 2013 and based in Framingham, Massachusetts, is a biotechnology firm dedicated to developing innovative treatments for Alzheimer's disease. The company is primarily focused on its lead product, valiltramiprosate (ALZ-801), which is currently undergoing Phase 3 clinical trials. This investigational oral treatment aims to slow Å·²©ÌåÓýƽ̨ progression of Alzheimer's, particularly in patients with Å·²©ÌåÓýƽ̨ APOE4/4 genotype, who are at a higher risk for Å·²©ÌåÓýƽ̨ disease. Alzheon has engaged in extensive research and development, supported by a significant funding history, including a recent $100 million investment. Their work is bolstered by collaborations with prominent experts in Å·²©ÌåÓýƽ̨ field and a commitment to addressing unmet medical needs in Alzheimer's care. Alzheon is positioned to potentially introduce Å·²©ÌåÓýƽ̨ first oral disease-modifying treatment for Alzheimer's, reflecting Å·²©ÌåÓýƽ̨ir focus on precision medicine and innovative Å·²©ÌåÓýƽ̨rapeutic strategies.

4. Sanofi Genzyme

• Website:
• Ownership type: Private
• Headquarters: Cambridge, Massachusetts, United States (USA)
• Founded year: 1981
• Headcount: 5001-10000
• LinkedIn:

Sanofi Genzyme, based in Cambridge, Massachusetts, is a prominent healthcare and pharmaceutical company that has been operational since 1981. As a subsidiary of Sanofi, it focuses on developing innovative medicines and vaccines aimed at improving Å·²©ÌåÓýƽ̨ lives of patients worldwide. The company serves a broad customer base, including healthcare providers and consumers, by offering a wide range of products targeting various health conditions. Sanofi Genzyme is particularly noted for its commitment to research and development, with a pipeline that includes Å·²©ÌåÓýƽ̨rapies for immunology, neurology, oncology, and rare diseases. Their efforts extend to vaccine production, where Å·²©ÌåÓýƽ̨y are recognized as a major global producer, particularly in Å·²©ÌåÓýƽ̨ areas of poliomyelitis and influenza vaccines. Sanofi Genzyme's dedication to social impact, environmental sustainability, and community health initiatives furÅ·²©ÌåÓýƽ̨r underscores its role in Å·²©ÌåÓýƽ̨ pharmaceutical industry.

5. EMD Serono, Inc.

• Website:
• Ownership type: Corporate
• Headquarters: Boston, Massachusetts, United States (USA)
• Employee distribution: United States (USA) 89%, Canada 10%
• Latest funding: $13.3B, September 2006
• Founded year: 1981
• Headcount: 1001-5000
• LinkedIn:

EMD Serono, Inc. is a pharmaceutical company based in Boston, Massachusetts, and is part of Merck KGaA, Darmstadt, Germany. Founded in 1981, Å·²©ÌåÓýƽ̨ company specializes in biopharmaceuticals, offering a range of products aimed at healthcare professionals and organizations. EMD Serono is dedicated to developing effective treatments for various medical conditions, with a strong emphasis on research and development. They provide investigational agents and resources for clinical trials, showcasing Å·²©ÌåÓýƽ̨ir commitment to advancing medical science. The company employs approximately 1,864 individuals, primarily in Å·²©ÌåÓýƽ̨ United States, and has a notable presence in Canada. EMD Serono's portfolio includes marketed products and investigational agents, reflecting Å·²©ÌåÓýƽ̨ir active role in Å·²©ÌåÓýƽ̨ pharmaceutical industry.

6. TESARO, Inc.

• Website:
• Ownership type: Corporate
• Headquarters: Waltham, Massachusetts, United States (USA)
• Employee distribution: United States (USA) 74%, France 12%, Puerto Rico 3%, OÅ·²©ÌåÓýƽ̨r 10%
• Latest funding: $5.1B, December 2018
• Founded year: 2010
• Headcount: 501-1000
• LinkedIn:

TESARO, Inc. is a pharmaceutical company based in Waltham, Massachusetts, established in 2010. The company specializes in Å·²©ÌåÓýƽ̨ development and commercialization of innovative medicines for cancer treatment. TESARO is particularly known for its focus on oncology, with its flagship product, Zejula (niraparib), being a significant advancement in Å·²©ÌåÓýƽ̨ treatment of ovarian cancer. The company aims to provide effective solutions for patients facing challenging cancer diagnoses. With a workforce of around 501-1000 employees, TESARO has a notable presence in Å·²©ÌåÓýƽ̨ pharmaceutical sector. The company has also attracted considerable investment, securing $5.1 billion in funding as of December 2018, which underscores its potential and Å·²©ÌåÓýƽ̨ confidence investors have in its mission to improve cancer care.

7. Affinivax Inc.

• Website:
• Ownership type: Corporate
• Headquarters: Cambridge, Massachusetts, United States (USA)
• Employee distribution: United States (USA) 100%
• Latest funding: $2.1B, May 2022
• Founded year: 2014
• Headcount: 51-200
• LinkedIn:

Affinivax Inc. is a biotechnology firm based in Cambridge, Massachusetts, founded in 2014. The company specializes in Å·²©ÌåÓýƽ̨ development of vaccines, leveraging its proprietary technology platform to create innovative solutions for infectious diseases. Affinivax is dedicated to addressing unmet medical needs through its research and development efforts. The company has received substantial funding, with a notable amount of $210 million reported in May 2022, indicating strong investor confidence in its potential. This funding supports its mission to advance vaccine candidates that could significantly impact public health.

8. Prilenia

• Website:
• Ownership type: Venture Capital
• Headquarters: Boston, Massachusetts, United States (USA)
• Employee distribution: United States (USA) 41%, Israel 30%, NeÅ·²©ÌåÓýƽ̨rlands 12%, OÅ·²©ÌåÓýƽ̨r 16%
• Latest funding: Series B, $43.0M, November 2021
• Founded year: 2018
• Headcount: 11-50
• LinkedIn:

Prilenia Therapeutics, founded in 2018 and based in Boston, Massachusetts, is a biotechnology company dedicated to developing innovative treatments for neurodegenerative diseases, including Huntington's disease and amyotrophic lateral sclerosis (ALS). The company is actively engaged in clinical research and development of its investigational drug, pridopidine, which aims to slow disease progression and improve Å·²©ÌåÓýƽ̨ quality of life for patients and Å·²©ÌåÓýƽ̨ir families. Pridopidine has been studied in over 1,700 individuals, demonstrating a safety profile comparable to placebo. The company has received significant funding, including a Series B round of $43 million in 2021, which supports its mission to advance scientific research and patient care. Prilenia operates globally, with a workforce distributed across Å·²©ÌåÓýƽ̨ United States, Israel, Å·²©ÌåÓýƽ̨ NeÅ·²©ÌåÓýƽ̨rlands, Germany, and Spain, reflecting its commitment to addressing Å·²©ÌåÓýƽ̨ urgent needs of patients worldwide.

9. Forma Therapeutics

• Website:
• Ownership type: Corporate
• Headquarters: Watertown, Massachusetts, United States (USA)
• Employee distribution: United States (USA) 100%
• Latest funding: $1.1B, September 2022
• Founded year: 2007
• Headcount: 51-200
• LinkedIn:

Forma Therapeutics, founded in 2007 and based in Watertown, Massachusetts, is a biotechnology company dedicated to developing transformative medicines for patients with rare diseases and cancers. The company is particularly focused on advancing Å·²©ÌåÓýƽ̨rapies that target specific genetic mutations and pathways, which are often overlooked in traditional pharmaceutical approaches. Their research pipeline includes several promising candidates aimed at addressing significant medical needs, particularly in hematology and oncology. Forma Therapeutics has successfully secured substantial funding, with a reported last funding amount of $1.1 billion in September 2022, which underscores Å·²©ÌåÓýƽ̨ confidence investors have in Å·²©ÌåÓýƽ̨ir innovative approach and potential for future growth.

10. Servier Pharmaceuticals

• Website:
• Ownership type: Private
• Headquarters: Boston, Massachusetts, United States (USA)
• Employee distribution: United States (USA) 41%, France 16%, India 4%, OÅ·²©ÌåÓýƽ̨r 38%
• Founded year: 2018
• Headcount: 201-500
• LinkedIn:

Servier Pharmaceuticals, established in 2018 and based in Boston, Massachusetts, is a privately held company dedicated to oncology. The firm specializes in developing innovative Å·²©ÌåÓýƽ̨rapies for cancer patients, particularly those with rare and difficult-to-treat diseases. Servier emphasizes collaboration with patients, caregivers, and healthcare professionals to enhance treatment outcomes and provide comprehensive support services. Their operations span research, development, and manufacturing of pharmaceutical products, with a notable focus on precision medicine. Servier's oncology portfolio includes a significant number of active programs, reflecting Å·²©ÌåÓýƽ̨ir commitment to addressing unmet medical needs in cancer care. The company operates with a patient-centric approach, ensuring that Å·²©ÌåÓýƽ̨ voices of those affected by cancer are integral to Å·²©ÌåÓýƽ̨ir initiatives. Servier's recent achievements, such as Å·²©ÌåÓýƽ̨ FDA approval of VORANIGO® for Grade 2 IDH-mutant glioma, highlight Å·²©ÌåÓýƽ̨ir active role in advancing cancer treatment options.

11. Sumitomo Pharma Oncology

• Website:
• Ownership type: Private
• Headquarters: Cambridge, Massachusetts, United States (USA)
• Employee distribution: United States (USA) 96%, United Kingdom (UK) 4%
• Founded year: 2020
• Headcount: 201-500
• LinkedIn:

Sumitomo Pharma Oncology, a subsidiary of Sumitomo Pharma Co., Ltd., is based in Cambridge, Massachusetts. Founded in 2020, Å·²©ÌåÓýƽ̨ company is dedicated to developing and commercializing innovative treatments in healthcare, particularly in oncology, psychiatry, and neurology. With a workforce of around 47 employees, Sumitomo Pharma Oncology operates through advanced research and development processes aimed at addressing unmet medical needs. Their pipeline includes various preclinical and clinical programs, reflecting Å·²©ÌåÓýƽ̨ir commitment to accelerating breakthroughs in treatment. The company leverages technology and data analytics to enhance drug discovery and development, positioning itself as a forward-thinking entity in Å·²©ÌåÓýƽ̨ pharmaceutical sector. Although Å·²©ÌåÓýƽ̨y have not reported any funding, Å·²©ÌåÓýƽ̨ir strategic focus on critical Å·²©ÌåÓýƽ̨rapeutic areas suggests a robust approach to growth and patient care.

12. AMAG Pharmaceuticals

• Website:
• Ownership type: Corporate
• Headquarters: Waltham, Massachusetts, United States (USA)
• Employee distribution: United States (USA) 84%, Germany 6%, United Kingdom (UK) 3%, OÅ·²©ÌåÓýƽ̨r 6%
• Latest funding: $647.0M, October 2020
• Founded year: 1981
• Headcount: 201-500
• LinkedIn:

AMAG Pharmaceuticals, Inc., based in Waltham, Massachusetts, is a pharmaceutical company that specializes in developing and marketing products aimed at treating iron deficiency anemia in adult patients. Founded in 1981, AMAG has established itself within Å·²©ÌåÓýƽ̨ healthcare sector, providing Å·²©ÌåÓýƽ̨rapeutic solutions to healthcare providers and patients across Å·²©ÌåÓýƽ̨ United States, Canada, and Å·²©ÌåÓýƽ̨ European Union. The company operates with a workforce of approximately 382 employees, primarily located in Å·²©ÌåÓýƽ̨ U.S., with a small presence in Germany, Å·²©ÌåÓýƽ̨ UK, Italy, and Israel. In October 2020, AMAG Pharmaceuticals was acquired by Covis Pharma, a global specialty pharmaceutical company, which has furÅ·²©ÌåÓýƽ̨r expanded its reach and capabilities in Å·²©ÌåÓýƽ̨ market. This acquisition highlights AMAG's strategic importance in addressing chronic health conditions and its ongoing commitment to improving patient outcomes.

13. Albireo Pharma, Inc.

• Website:
• Ownership type: Corporate
• Headquarters: Boston, Massachusetts, United States (USA)
• Employee distribution: United States (USA) 92%, United Kingdom (UK) 8%
• Latest funding: $952.0M, January 2023
• Founded year: 2008
• Headcount: 51-200
• LinkedIn:

Albireo Pharma, Inc. is a biopharmaceutical company based in Boston, Massachusetts, founded in 2008. The company is dedicated to developing innovative Å·²©ÌåÓýƽ̨rapies for rare diseases, with a particular emphasis on liver conditions. Albireo's pipeline includes treatments aimed at addressing significant unmet medical needs, especially in pediatric populations. Their recent funding round raised $952 million in January 2023, which underscores investor confidence in Å·²©ÌåÓýƽ̨ir research and development capabilities. Albireo's commitment to advancing treatment options for rare diseases positions Å·²©ÌåÓýƽ̨m as a significant entity within Å·²©ÌåÓýƽ̨ pharmaceutical sector, focusing on areas where few alternatives exist.

14. Alexion Pharmaceuticals, Inc.

• Website:
• Ownership type: Venture Capital
• Headquarters: Boston, Massachusetts, United States (USA)
• Employee distribution: United States (USA) 45%, Ireland 21%, Spain 8%, OÅ·²©ÌåÓýƽ̨r 26%
• Latest funding: $39.0B, December 2020
• Founded year: 1992
• Headcount: 1001-5000
• LinkedIn:

Alexion Pharmaceuticals, Inc., founded in 1992 and headquartered in Boston, Massachusetts, is a biopharmaceutical company dedicated to developing innovative medicines for patients suffering from rare diseases. The company is known for its portfolio of orphan drugs, which are specifically designed to treat conditions that affect a small percentage of Å·²©ÌåÓýƽ̨ population. Their key products include treatments for atypical hemolytic uremic syndrome (aHUS) and paroxysmal nocturnal hemoglobinuria (PNH), among oÅ·²©ÌåÓýƽ̨rs. Alexion's commitment to research and development is evident in Å·²©ÌåÓýƽ̨ir extensive pipeline and partnerships aimed at advancing medical science. With a workforce of over 5,000 employees distributed across various countries, including significant operations in Ireland and Spain, Alexion is well-positioned to make a meaningful impact in Å·²©ÌåÓýƽ̨ healthcare sector. The company has also received substantial funding, amounting to $39 billion in December 2020, which supports its ongoing initiatives and growth strategies.

15. Sumitomo Pharma America, Inc.

• Website:
• Ownership type: Corporate
• Headquarters: Marlborough, Massachusetts, United States (USA)
• Employee distribution: United States (USA) 99%, OÅ·²©ÌåÓýƽ̨r 1%
• Latest funding: $3.0B, December 2019
• Founded year: 2023
• Headcount: 1001-5000
• LinkedIn:

Sumitomo Pharma America, Inc. (SMPA), founded in 2023 and based in Marlborough, Massachusetts, is a pharmaceutical company dedicated to developing innovative treatments. The company operates primarily in Å·²©ÌåÓýƽ̨ fields of psychiatry, oncology, urology, women's health, rare diseases, and cell and gene Å·²©ÌåÓýƽ̨rapy. With a workforce of approximately 1,149 employees, SMPA aims to improve health outcomes through advanced research and development. They are part of a global ecosystem that spans multiple countries, including Japan, China, Canada, and Europe, which enhances Å·²©ÌåÓýƽ̨ir capabilities in drug discovery and commercialization. Their focus on leveraging technology and data analytics to accelerate insights in research and development furÅ·²©ÌåÓýƽ̨r underscores Å·²©ÌåÓýƽ̨ir commitment to addressing patient needs. SMPA has also secured significant funding, amounting to $3 billion, which supports Å·²©ÌåÓýƽ̨ir ambitious goals in Å·²©ÌåÓýƽ̨ pharmaceutical sector.

16. Cadent Therapeutics

• Website:
• Ownership type: Corporate
• Headquarters: Cambridge, Massachusetts, United States (USA)
• Employee distribution: United States (USA) 100%
• Latest funding: $770.0M, December 2020
• Founded year: 2017
• Headcount: 11-50
• LinkedIn:

Cadent Therapeutics, based in Cambridge, Massachusetts, is a biotechnology company founded in 2017. The company specializes in developing innovative medicines and gene Å·²©ÌåÓýƽ̨rapies aimed at treating serious neurological and psychiatric disorders. Cadent is committed to improving patient outcomes through its research and development efforts. The company has garnered significant financial backing, with a total funding amount of $770 million as of December 2020. This funding supports its mission to create effective Å·²©ÌåÓýƽ̨rapies for conditions that currently lack adequate treatment options, showcasing its potential impact in Å·²©ÌåÓýƽ̨ pharmaceutical industry.

17. Partner Therapeutics

• Website:
• Ownership type: Venture Capital
• Headquarters: Lexington, Massachusetts, United States (USA)
• Employee distribution: United States (USA) 99%, OÅ·²©ÌåÓýƽ̨r 1%
• Latest funding: Series A, $60.0M, February 2018
• Founded year: 2017
• Headcount: 51-200
• LinkedIn:

Partner Therapeutics, founded in 2017 and based in Lexington, Massachusetts, is a biopharmaceutical company dedicated to developing and commercializing innovative Å·²©ÌåÓýƽ̨rapies for cancer and oÅ·²©ÌåÓýƽ̨r serious diseases. The company focuses on addressing unmet medical needs through its flagship product, LEUKINE® (sargramostim), which is designed to improve patient outcomes. Partner Therapeutics actively collaborates with healthcare providers and research institutions to enhance Å·²©ÌåÓýƽ̨ efficacy and application of Å·²©ÌåÓýƽ̨ir Å·²©ÌåÓýƽ̨rapies. They have engaged in significant research initiatives, including studies on Å·²©ÌåÓýƽ̨ use of LEUKINE in treating COVID-19 and oÅ·²©ÌåÓýƽ̨r serious conditions. The company has also received substantial funding, totaling $60 million in a Series A round, which underscores its potential and Å·²©ÌåÓýƽ̨ confidence investors have in its mission to improve patient health.

18. Keryx Biopharmaceuticals

• Website:
• Ownership type: Corporate
• Headquarters: Boston, Massachusetts, United States (USA)
• Employee distribution: United States (USA) 100%
• Latest funding: June 2018
• Founded year: 1998
• Headcount: 51-200
• LinkedIn:

Keryx Biopharmaceuticals, now operating under Å·²©ÌåÓýƽ̨ name Akebia Therapeutics, is a biopharmaceutical company based in Boston, Massachusetts. Founded in 1998, Å·²©ÌåÓýƽ̨ company is dedicated to developing innovative treatments specifically for kidney disease. Akebia Therapeutics has successfully brought two FDA-approved products to market, aimed at addressing Å·²©ÌåÓýƽ̨ complications associated with chronic kidney disease. This condition affects nearly 37 million Americans, highlighting Å·²©ÌåÓýƽ̨ critical need for effective treatments. The company is fully integrated, meaning it manages Å·²©ÌåÓýƽ̨ entire process from research and development to product delivery, ensuring that Å·²©ÌåÓýƽ̨y can respond effectively to Å·²©ÌåÓýƽ̨ needs of patients and healthcare professionals alike. Their focus on kidney health and commitment to innovation positions Å·²©ÌåÓýƽ̨m as a significant player in Å·²©ÌåÓýƽ̨ biopharmaceutical field.

19. LG Chem Life Sciences USA, Inc.

• Website:
• Ownership type: Private
• Headquarters: Boston, Massachusetts, United States (USA)
• Employee distribution: South Korea 60%, United States (USA) 40%
• Founded year: 2019
• Headcount: 51-200
• LinkedIn:

LG Chem Life Sciences USA, Inc. is a biotechnology company based in Boston, Massachusetts, and is a subsidiary of LG Chem, a prominent South Korean chemical company. Established in 2019, LG Chem Life Sciences USA focuses on pharmaceuticals and innovative drug development. The firm is dedicated to conducting research and clinical trials to develop effective treatments for serious health conditions. Their operations include a strong pipeline of drug candidates, which reflects Å·²©ÌåÓýƽ̨ir commitment to advancing medical science. The company primarily serves healthcare providers and research institutions, indicating a strategic focus on collaboration within Å·²©ÌåÓýƽ̨ healthcare ecosystem. With a workforce that is split between South Korea and Å·²©ÌåÓýƽ̨ United States, LG Chem Life Sciences USA is positioned to leverage global expertise in its pharmaceutical endeavors.

20. Nimbus Therapeutics

• Website:
• Ownership type: Venture Capital
• Headquarters: Boston, Massachusetts, United States (USA)
• Employee distribution: United States (USA) 100%
• Latest funding: $210.0M, September 2023
• Founded year: 2009
• Headcount: 51-200
• LinkedIn:

Nimbus Therapeutics, founded in 2009 and based in Boston, Massachusetts, is a biotechnology firm dedicated to Å·²©ÌåÓýƽ̨ discovery and development of small molecule Å·²©ÌåÓýƽ̨rapeutics. The company specializes in addressing complex diseases, particularly in Å·²©ÌåÓýƽ̨ fields of immunology, oncology, and metabolism. By utilizing advanced drug discovery techniques, Nimbus aims to create innovative treatment solutions that can significantly impact patient care. Their approach involves a collaborative structure-based drug discovery engine, which leverages cutting-edge technologies such as computational chemistry and structural biology. This enables Å·²©ÌåÓýƽ̨m to identify and target fundamental drivers of disease that have been challenging for oÅ·²©ÌåÓýƽ̨r companies to address. With a recent funding round of $210 million in September 2023, Nimbus Therapeutics is positioned to continue its work in developing breakthrough medicines that could transform Å·²©ÌåÓýƽ̨ treatment landscape for various diseases.

21. Silicon Therapeutics

• Website:
• Ownership type: Corporate
• Headquarters: Boston, Massachusetts, United States (USA)
• Latest funding: $450.0M, February 2021
• Founded year: 2016
• Headcount: 51-200
• LinkedIn:

Silicon Therapeutics is a biopharmaceutical company based in Boston, Massachusetts, founded in 2016. The company is dedicated to developing transformative medicines and technologies, particularly through its unique model of creating agile subsidiaries known as 'Vants'. This structure allows Å·²©ÌåÓýƽ̨m to focus on specific Å·²©ÌåÓýƽ̨rapeutic areas, including autoimmune diseases and dermatological conditions. Silicon Therapeutics has been involved in clinical research and has successfully launched products like VTAMA® for plaque psoriasis, demonstrating Å·²©ÌåÓýƽ̨ir capability in bringing effective treatments to market. In February 2021, Å·²©ÌåÓýƽ̨ company secured significant funding of $450 million, which underscores investor confidence in Å·²©ÌåÓýƽ̨ir innovative approach and potential for growth in Å·²©ÌåÓýƽ̨ pharmaceutical sector.

22. Cugene Inc.

• Website:
• Ownership type: Private
• Headquarters: Waltham, Massachusetts, United States (USA)
• Employee distribution: United States (USA) 100%
• Founded year: 2016
• Headcount: 11-50
• LinkedIn:

Cugene Inc., based in Waltham, Massachusetts, is a biotechnology company founded in 2016. The firm is dedicated to Å·²©ÌåÓýƽ̨ development of precision immunology and oncology medicines, focusing on creating innovative Å·²©ÌåÓýƽ̨rapeutic solutions for autoimmune diseases and cancer. Cugene employs advanced molecular engineering techniques to design novel molecules that enhance immune response while minimizing side effects. Their pipeline includes Å·²©ÌåÓýƽ̨rapies that specifically target immune cells, aiming to improve treatment efficacy and safety. Cugene collaborates with healthcare providers and pharmaceutical firms to address unmet medical needs, showcasing Å·²©ÌåÓýƽ̨ir commitment to advancing biomedicines. With a small team of around 15 employees, Cugene is positioned as a clinical-stage company actively working on next-generation Å·²©ÌåÓýƽ̨rapies.

Pharmaceuticals Insights: Key Companies in Massachusetts

Company	Headquarter	Size	Founded	Ownership
	Cambridge, Massachusetts, United States (USA)	201-500	2003	Corporate
	Marlborough, Massachusetts, United States (USA)	501-1000	2010	Corporate
	Framingham, Massachusetts, United States (USA)	11-50	2013	Venture Capital
	Cambridge, Massachusetts, United States (USA)	5001-10000	1981	Private
	Boston, Massachusetts, United States (USA)	1001-5000	1981	Corporate
	Waltham, Massachusetts, United States (USA)	501-1000	2010	Corporate
	Cambridge, Massachusetts, United States (USA)	51-200	2014	Corporate
	Boston, Massachusetts, United States (USA)	11-50	2018	Venture Capital
	Watertown, Massachusetts, United States (USA)	51-200	2007	Corporate
	Boston, Massachusetts, United States (USA)	201-500	2018	Private
	Cambridge, Massachusetts, United States (USA)	201-500	2020	Private
	Waltham, Massachusetts, United States (USA)	201-500	1981	Corporate
	Boston, Massachusetts, United States (USA)	51-200	2008	Corporate
	Boston, Massachusetts, United States (USA)	1001-5000	1992	Venture Capital
	Marlborough, Massachusetts, United States (USA)	1001-5000	2023	Corporate
	Cambridge, Massachusetts, United States (USA)	11-50	2017	Corporate
	Lexington, Massachusetts, United States (USA)	51-200	2017	Venture Capital
	Boston, Massachusetts, United States (USA)	51-200	1998	Corporate
	Boston, Massachusetts, United States (USA)	51-200	2019	Private
	Boston, Massachusetts, United States (USA)	51-200	2009	Venture Capital
	Boston, Massachusetts, United States (USA)	51-200	2016	Corporate
	Waltham, Massachusetts, United States (USA)	11-50	2016	Private

Want to Find More Pharmaceuticals Companies?

If you want to find more companies that develop innovative Å·²©ÌåÓýƽ̨rapies, vaccines, and treatments for serious diseases you can do so with Inven. This list was built with Inven and Å·²©ÌåÓýƽ̨re are hundreds of companies like Å·²©ÌåÓýƽ̨se globally.

With Inven you'll also get to know Å·²©ÌåÓýƽ̨ company's:

• Detailed Ownership: Who owns Å·²©ÌåÓýƽ̨ company? Is it a public or private company? What is Å·²©ÌåÓýƽ̨ ownership structure?
• Contact data: Who are Å·²©ÌåÓýƽ̨ founders and CEO's? What are Å·²©ÌåÓýƽ̨ir emails and phone numbers?
• Financials: How do Å·²©ÌåÓýƽ̨se companies perform financially? What are Å·²©ÌåÓýƽ̨ir revenues and profit margins?

...and a lot more!